Organization and Business Activities (Details)	0 Months Ended		1 Months Ended	9 Months Ended	1 Months Ended		3 Months Ended
	Apr. 09, 2012 Vancocin item	Dec. 14, 2011 Vancocin	Jun. 30, 2012 Vancocin item	Sep. 30, 2013 Vancocin item	Sep. 30, 2011 Buccolam Maximum	Sep. 30, 2011 Buccolam Minimum	Jun. 30, 2012 Maribavir item
Organization and business activities disclosures
Age of children and adolescents for the purpose of being eligible for treatment					18 years	3 months
Additional years of exclusivity not qualified		3 years
Number of ANDAs approved	3		4
Royalties obligated to be paid as percentage of net sales in year one after approval of sNDA				10.00%
Royalties obligated to be paid as percentage of net sales in year two after approval of sNDA				10.00%
Royalties obligated to be paid as percentage of net sales in year three after approval of sNDA				16.00%
Exclusive rights to studies of Vancocin				2
Number of Phase 2 clinical studies							2